The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaTCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaManagement of Chronic Lymphocytic Leukemia in the ElderlyPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateIbrutinib (PCI-32765) in chronic lymphocytic leukemiaThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibTargeted therapies in CLL: mechanisms of resistance and strategies for managementB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292How will B-cell-receptor-targeted therapies change future CLL therapy?The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSignal transduction in the chronic leukemias: implications for targeted therapiesIbrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseResistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaB-cell receptor signalling and its crosstalk with other pathways in normal and malignant cellsIbrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisDasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaIbrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Tyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophagesIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialIbrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibitionUsing high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsTargeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaIbrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLChanges in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
P2860
Q26748775-6694026F-CD2C-4663-9E10-7F7974ADA693Q26764833-98761328-1B97-497E-A128-028CE229112FQ26765624-6566B078-31E0-4808-894C-45268C0D31BBQ26773053-519B91C4-E451-478D-B7BF-D14F03B27C34Q26775506-82D38C71-2209-4ED7-84AC-0EB76E2EBC4EQ26775983-7DFF7B53-4415-454A-A833-B7505350C9E4Q26782633-17A13F59-35D9-40FA-9096-32F875A464A2Q26798062-361FA01F-B4A5-4963-9650-BA761D352542Q26852328-DD4AF70E-F9CE-47AA-8B17-FA44B2B3BD28Q26865760-A9949D4D-2FCF-452F-917B-40AE787131ADQ26991890-19FC97E5-13BE-421D-A85A-E0CFEC48C5B2Q26995113-4DEB25B1-5D15-4D05-AE17-67031E809483Q27002528-7C454C45-CDDC-40EB-893E-59FFE28F26E9Q27009550-6CEF833F-1933-4CBF-A421-6B4E893B2E73Q27024187-82BAAF67-B50B-4CD9-8313-B230F7902780Q27024411-E27BA4CE-CFFF-4FEF-8608-269B6B24C516Q27025812-F73B2116-EB1B-4A02-AA66-EBBBA793FCE4Q27026031-35B7C57A-F97C-4778-B6F7-E24C87D1ED7EQ27026912-27561A65-72B8-4DFF-AD56-83815391A720Q27304652-0919EAC7-C09F-4BF3-94E4-367544E2F43BQ27853011-28718C7B-A53D-4391-B0A2-690D3FB9480FQ28081162-0A66F97E-2C63-4CCD-9E99-C054397D861DQ28087378-7381F41F-C355-4526-B343-4751EF19E2E5Q28245018-7499514E-17D8-45CD-A807-4226E3132547Q28277551-0311CAE0-F5C2-4F2D-BE10-13D7BFDE8791Q28484839-965CE30B-0732-441D-874F-21BB5FD29E81Q29620690-E882A6A9-A749-48AE-87EB-0BE4BF4DF0A0Q30252869-DFFA5C67-E37E-49C6-A3E9-6FFEEE06B032Q30303054-5F8B9DE0-C873-4321-97AF-6AEA1F082A72Q30615575-1FBE6B98-213E-4A4B-964A-CA3913E64019Q33412064-80CD9DC4-FBFE-4FC3-9003-242CA87F5521Q33566063-A5D566D0-1555-45CC-8B9B-86DB63C67A0AQ33566747-DFD759AC-3336-496F-A63E-13AE6C70BFD4Q33587826-F3A2DFF2-0A77-4A04-97FD-E3D3CB644AA8Q33714712-BEE6EA51-FA83-4AF2-98DC-D720EE00FBB1Q33798525-80E4EDC7-AF5C-4EED-BA2D-2C556794923AQ33893704-400FD4DC-6803-4EC6-BD62-16D126B5280EQ33924158-19D61767-82D7-4F15-A038-8A6224CC3049Q34009064-46876DB3-7C47-4C94-B980-58C6C71C2583Q34020276-630547E5-2704-4474-A381-F92F009B9364
P2860
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@ast
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@en
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@nl
type
label
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@ast
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@en
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@nl
prefLabel
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@ast
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@en
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@nl
P2093
P2860
P50
P921
P1433
P1476
The Bruton tyrosine kinase inh ...... e homing in vitro and in vivo.
@en
P2093
Jan A Burger
Joseph J Buggy
Kumudha Balakrishnan
Nicholas Chiorazzi
Sabine Ponader
Shih-Shih Chen
Varsha Gandhi
P2860
P304
P356
10.1182/BLOOD-2011-10-386417
P407
P577
2011-12-16T00:00:00Z